| Literature DB >> 31506096 |
Elizabeth Hibler1, Lei Huang2, Jorge Andrade2,3, Bonnie Spring4.
Abstract
BACKGROUND: Studies demonstrate the impact of diet and physical activity on epigenetic biomarkers, specifically DNA methylation. However, no intervention studies have examined the combined impact of dietary and activity changes on the blood epigenome. The objective of this study was to examine the impact of the Make Better Choices 2 (MBC2) healthy diet and activity intervention on patterns of epigenome-wide DNA methylation. The MBC2 study was a 9-month randomized controlled trial among adults aged 18-65 with non-optimal levels of health behaviors. The study compared three 12-week interventions to (1) simultaneously increase exercise and fruit/vegetable intake, while decreasing sedentary leisure screen time; (2) sequentially increase fruit/vegetable intake and decrease leisure screen time first, then increase exercise; (3) increase sleep and decrease stress (control). We collected blood samples at baseline, 3 and 9 months, and measured DNA methylation using the Illumina EPIC (850 k) BeadChip. We examined region-based differential methylation patterns using linear regression models with the false discovery rate of 0.05. We also conducted pathway analysis using gene ontology (GO), KEGG, and IPA canonical pathway databases.Entities:
Keywords: DNA methylation; Diet; Lifestyle; Physical activity; Randomized trial
Mesh:
Year: 2019 PMID: 31506096 PMCID: PMC6737702 DOI: 10.1186/s13148-019-0707-0
Source DB: PubMed Journal: Clin Epigenetics ISSN: 1868-7075 Impact factor: 6.551
Baseline characteristics of the DNA methylation subsample from the MBC2 population
| Participant characteristics | DNA methylation ( | No DNA methylation ( | ||||
|---|---|---|---|---|---|---|
| Control ( | Simultaneous ( | Sequential ( | Control ( | Simultaneous ( | Sequential ( | |
| Age, mean (SD) | 41.9 (12.6) | 41.4 (12.3) | 41.6 (10.1) | 40.2 (12.6) | 40.5 (11.7) | 40.5 (11.4) |
| BMI, mean (SD) | 32.6 (6.9) | 34.5 (8.0) | 37.3 (7.5) | 34.7 (8.5) | 34.1 (9.2) | 35.5 (11.0) |
| Female, | 27 (87.1) | 55 (80.9) | 8 (66.7) | 38 (71.7) | 107 (74.3) | 25 (78.1) |
| Ethnicity, | ||||||
| Hispanic or Latino | 4 (13.3) | 6 (9.5) | 1 (9.1) | 5 (9.6) | 14 (10.0) | 5 (15.6) |
| Non-Hispanic or Latino | 26 (86.7) | 58 (92.1) | 10 (90.1) | 47 (90.4) | 126 (90.0) | 27 (84.4) |
| Race, | ||||||
| White | 16 (51.6) | 30 (44.1) | 5 (41.7) | 24 (45.3) | 57 (39.6) | 14 (43.8) |
| Black | 14 (45.2) | 34 (50.0) | 6 (50.0) | 24 (45.3) | 65 (45.1) | 13 (40.6) |
| Asian | 0 | 2 (3.1) | 1 (8.3) | 1 (1.9) | 6 (4.2) | 1 (3.1) |
| Other or multiple | 1 (3.2) | 2 (3.1) | 0 | 4 (7.5) | 16 (11.1) | 4 (12.5) |
Top 10 differentially methylation regions for 3-month control vs. pooled sequential/simultaneous
| Region coordinates | Genes in region | Gene function [ | # CpGs | FDR | Stouffer | ||
|---|---|---|---|---|---|---|---|
| chr1:228756711–228756714 |
| Pseudogene for MAPK phosphatase, proposed as a tumor suppressor in hematopoietic cancers [ | 2 | 0.0036 | 0.7466 | − 0.1183 | − 0.1183 |
| chr19:37463254–37463280 |
| Role in transcriptional repression during embryonic development. Potential role in sessile serrated colon polyps [ | 2 | 0.0013 | 0.7671 | 0.0787 | 0.0549 |
| chr20:58662458–58662959 |
| N/A | 2 | 0.0029 | 0.7729 | − 0.0878 | − 0.0791 |
| chr3:119499749–119500059 |
| Transcription factor regulating detoxification and xenobiotic metabolism [ | 2 | 0.0004 | 0.8361 | 0.0982 | 0.0625 |
| chr1:229764652–229764706 |
| Ribosomal biosynthesis | 2 | 0.0059 | 0.8873 | 0.0622 | 0.0351 |
| chr2:105990524–105991411 |
| Assembly of extracellular membranes and used in models estimating epigenetic aging [ | 3 | 0.0013 | 0.8891 | 0.0539 | 0.0448 |
| chr5:488398–488527 |
| Sodium biocarbonate cotransporter. Regulation of intracellular pH and renal tubular function [ | 2 | 0.0141 | 0.8900 | 0.0660 | 0.0493 |
| chr3:46599958–46600244 |
| N/A | 2 | 0.0147 | 0.8921 | 0.0738 | 0.0568 |
| chr1:187445635–187445942 |
| Long intergenic non-protein coding RNA 1037 | 2 | 0.0233 | 0.8955 | − 0.0617 | − 0.0354 |
| chr4:185369135–185370076 |
| Competitively inhibits the IRF1-mediated transcriptional activation of interferons alpha and beta. Decreased expression is associated with angiogenesis and inflammation [ | 3 | 0.0029 | 0.8977 | − 0.1266 | − 0.1005 |
Top 10 differentially methylation regions for 9-month control vs. pooled sequential/simultaneous
| Region coordinates | Genes in region | Gene function [ | # CpGs | FDR | Stouffer | ||
|---|---|---|---|---|---|---|---|
| chr8:51306070–51306693 |
| Mediates dystrophin binding. Associated with idiopathic scoliosis [ | 3 | 2.49E− 09 | 0.0904 | 0.2066 | 0.1012 |
| chr3:150265617–150265620 |
| Protein folding and metabolism. Inhibition can downregulate the Wnt/β-catenin pathway in keratinocytes [ | 2 | 4.96E− 06 | 0.1754 | 0.0351 | 0.0327 |
| chr3:44636619–44636844 |
| Transcription factor with potential role in skeletal muscle energy metabolism following exercise [ | 2 | 0.0008 | 0.3556 | 0.0465 | 0.0267 |
| chr22:49875144–49875295 |
| Chromosome 22 Open Reading Frame 34, uncharacterized protein. | 2 | 0.0040 | 0.3980 | − 0.0775 | − 0.0575 |
| chr16:1477870–1478718 |
| Chromosome 16 Open Reading Frame 91, uncharacterized protein. | 3 | 0.0001 | 0.4290 | − 0.0667 | − 0.0434 |
| chr19:7813422–7813963 |
| Pseudogene, unknown function. | 3 | 3.81E− 06 | 0.4426 | − 0.0800 | − 0.0468 |
| chr13:101173617–101174420 |
| Subunit of mitochondrial enzyme critical to energy metabolism [ | 8 | 4.01E− 11 | 0.4572 | − 0.0929 | − 0.0537 |
| chr11:1903176–1903333 |
| Expressed in immune system cells and may regulate motility and transendothelial migration. Potential marker of hepatocellular carcinoma risk [ | 2 | 0.0047 | 0.4611 | − 0.0586 | − 0.0486 |
| chr4:185369135–185370076 |
| Competitively inhibits the IRF1-mediated transcriptional activation of interferons alpha and beta. Decreased expression associated with angiogenesis and inflammation [ | 3 | 0.0030 | 0.4752 | − 0.1271 | − 0.0100 |
| chr4:175241684–175241753 |
| Centrosomal protein | 2 | 0.0071 | 0.4980 | − 0.1368 | − 0.0847 |
| chr17:72915897–72916509 |
| Auditory and visual function development [ | 3 | 0.0009 | 0.5005 | − 0.0636 | − 0.0595 |
Gene ontology results by time point from control versus pooled sequential/simultaneous
| Time point | ID | Description | Gene ratio | ||
|---|---|---|---|---|---|
| 3 months | GO:0007156 | Homophilic cell adhesion via plasma-membrane adhesion molecules | 23/123 | 6.59E−25 | 1.28E−21 |
| GO:0098742 | Cell-cell adhesion via plasma-membrane adhesion molecules | 23/123 | 5.15E−21 | 4.95E−18 | |
| 9 months | GO:0007156 | Homophilic cell adhesion via plasma-membrane adhesion molecules | 24/221 | 3.91E−20 | 1.23E−16 |
| GO:0098742 | Cell-cell adhesion via plasma-membrane adhesion molecules | 25/221 | 2.87E−17 | 4.50E−14 |
Top 20 IPA Canonical Pathways by time point for control versus pool sequential/simultaneous
| Ingenuity canonical pathways | −log ( | Ratio |
|---|---|---|
| 3 months | ||
| GDP- | 1.89 | 0.500 |
| Methylmalonyl pathway | 1.59 | 0.250 |
| 2-Oxobutanoate degradation I | 1.49 | 0.200 |
| PI3K/AKT signaling | 1.33 | 0.024 |
| GM-CSF signaling | 1.08 | 0.027 |
| Colanic acid building blocks biosynthesis | 1.06 | 0.071 |
| Wnt/β-catenin signaling | 1.01 | 0.018 |
| Mitochondrial | 0.98 | 0.059 |
| Bladder cancer signaling | 0.96 | 0.023 |
| GADD45 signaling | 0.93 | 0.053 |
| Acute myeloid leukemia signaling | 0.92 | 0.022 |
| Inflammasome pathway | 0.91 | 0.050 |
| Pyrimidine deoxyribonucleotides de novo biosynthesis I | 0.85 | 0.044 |
| Estrogen-mediated S-phase entry | 0.81 | 0.039 |
| Sonic hedgehog signaling | 0.76 | 0.035 |
| Sperm motility | 0.73 | 0.017 |
| LXR/RXR activation | 0.73 | 0.017 |
| FXR/RXR activation | 0.71 | 0.016 |
| Circadian rhythm signaling | 0.70 | 0.029 |
| 9 months | ||
| GDP- | 1.65 | 0.500 |
| Estrogen-mediated S-phase entry | 1.47 | 0.077 |
| Glioblastoma multiforme signaling | 1.45 | 0.031 |
| p53 signaling | 1.44 | 0.036 |
| Methylmalonyl pathway | 1.36 | 0.250 |
| PI3K/AKT signaling | 1.30 | 0.033 |
| 2-Oxobutanoate degradation I | 1.26 | 0.200 |
| Cell cycle regulation by BTG family proteins | 1.19 | 0.054 |
| NAD biosynthesis from 2-amino-3-carboxymuconate semialdehyde | 1.18 | 0.167 |
| nNOS signaling in skeletal muscle cells | 1.13 | 0.050 |
| Bladder cancer signaling | 1.13 | 0.035 |
| Phosphatidylcholine biosynthesis I | 1.12 | 0.143 |
| tRNA splicing | 1.11 | 0.049 |
| Ovarian cancer signaling | 1.11 | 0.028 |
| Role of p14/p19ARF in tumor suppression | 1.09 | 0.048 |
| Phosphatidylethanolamine biosynthesis II | 1.06 | 0.125 |
| Gustation pathway | 1.05 | 0.027 |
| GABA receptor signaling | 1.05 | 0.032 |
| Role of Oct4 in mammalian embryonic stem cell pluripotency | 1.04 | 0.044 |